{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:13:44Z","timestamp":1758820424151},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,3,22]],"date-time":"2007-03-22T00:00:00Z","timestamp":1174521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Seborrhoeic dermatitis (SD) is a common dermatosis in human immunodeficiency virus (HIV)\u2010positive patients, many of whom do not respond satisfactorily to conventional topical treatments such as corticosteroids and antifungals.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> A pilot study to investigate the efficacy and tolerability of pimecrolimus cream 1% in HIV\u2010positive patients with facial SD.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> In a single\u2010centre study, 21 HIV\u2010infected patients with mild to severe SD were treated twice daily with pimecrolimus cream 1% for 14\u00a0days. Thereafter, treatment was discontinued and patients followed up for 5\u00a0weeks. Skin involvement at baseline and on days 7, 14, 21, 35 and 49 was assessed using a four\u2010point clinical score and digital photography.<\/jats:p><jats:p><jats:bold>Main outcome measures\u2002<\/jats:bold> Efficacy and safety of pimecrolimus cream 1% treatment and incidence of relapse in the follow\u2010up phase.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Marked improvement was seen in clinical parameters at day\u00a07, with \u2265\u00a090% patients clear of symptoms at day\u00a014. Relapse was observed at day\u00a035 but signs were milder than at baseline. All patients responded to therapy, despite their immunological status. Pimecrolimus did not alter CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T\u2010cell counts or viral load during the treatment period.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Pimecrolimus cream represents a new, effective therapeutic option for facial SD in HIV patients.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2006.01923.x","type":"journal-article","created":{"date-parts":[[2007,3,22]],"date-time":"2007-03-22T12:48:12Z","timestamp":1174567692000},"page":"596-601","source":"Crossref","is-referenced-by-count":24,"title":["An open\u2010label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV"],"prefix":"10.1111","volume":"21","author":[{"given":"AP","family":"De Moraes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9\u00c2G","family":"De Arruda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAV","family":"Vitoriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MO","family":"De Moraes Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00c2F","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"De Magalh\u00e3es Holanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MEA","family":"De Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,22]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000076478"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.00693.x"},{"key":"e_1_2_5_4_2","first-page":"1482","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"Jansen T","year":"1999"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000018087"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246404"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0733-8635(18)30122-0","article-title":"Treatment of skin diseases in HIV infected patients","volume":"13","author":"Thiers BH","year":"1995","journal-title":"Dermatol Clin"},{"key":"e_1_2_5_8_2","first-page":"207","article-title":"Pimecrolimus: a new treatment for seborrheic dermatitis","volume":"70","author":"Crutchfield CE","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/sder.2001.29060"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.3.643"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000086739"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.051"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5070\/D39ZQ059N5","article-title":"Topical pimecrolimus in the treatment of seborrheic dermatitis","volume":"9","author":"Brownell I","year":"2003","journal-title":"Dermatol Online J"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06208.x"},{"key":"e_1_2_5_15_2","first-page":"111","article-title":"Facial seborrheic dermatitis treated with pimecrolimus cream in four patients HIV positive","volume":"5","author":"Moraes AP","year":"2004","journal-title":"J Brasileiro Aids"},{"issue":"1","key":"e_1_2_5_16_2","first-page":"54","article-title":"Is seborrhoeic dermatitis a clinical marker of HIV disease?","volume":"52","author":"Ippolito F","year":"2000","journal-title":"Minerva Ginecol"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70173-F"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2006.01923.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2006.01923.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:37:30Z","timestamp":1696966650000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2006.01923.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,22]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1111\/j.1468-3083.2006.01923.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01923.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,22]]}}}